Mergers & Acquisitions ·
MiMedx Group, Inc. entered into a definitive merger agreement to acquire Sanara MedTech Inc. for approximately $350…
MDXGMimedx Group, Inc.
MiMedx Group, Inc. entered into a definitive merger agreement to acquire Sanara MedTech Inc. for approximately $350 million in enterprise value. The transaction values each share of Sanara common stock at $35.00, consisting of $33.00 per share in cash and 0.4735 shares of MiMedx common stock valued at $2.00 per share based on the five-day average closing price prior to July 29, 2026. MiMedx will finance the cash portion using existing cash and a new $300 million senior secured term loan facility from Hayfin Capital Management, LLP, which will replace its existing credit agreement. The boards of both companies unanimously approved the deal, which is expected to close by year-end 2026 subject to Sanara shareholder approval and regulatory clearances. MiMedx operates in the regenerative medicine sector, providing biological products for wound care, burn treatment, and surgical applications.